WooGene B&G Co., Ltd

A018620

KR7018620005

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 13/06/2024 am IST			5-day change	1st Jan Change
1,163 ^KRW	-0.34%		-0.51%	-5.06%

20/03	WooGene B&G Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	WooGene B&G Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

WooGene B&G Co., Ltd. Extends Equity Buyback till May 2, 2014

April 30, 2013 at 09:30 am IST

On April 30, 2013, the Board of Directors of WooGene B&G Co., Ltd. announced that it has extended the program till May 2, 2014.

Latest news about WooGene B&G Co., Ltd

WooGene B&G Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
WooGene B&G Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
WooGene B&G Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
WooGene B&G Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
WooGene B&G Co., Ltd announced that it has received KRW 8 billion in funding	23/23/23	CI
WooGene B&G Co., Ltd announced that it expects to receive KRW 8 billion in funding	21/23/21	CI
WooGene B&G Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
WooGene B&G Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
WooGene B&G Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
WooGene B&G Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22/22/22	CI
WooGene B&G Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/21/12	CI
An unknown buyer cancelled the acquisition of 23.2% stake in WooGene Bio Co., Ltd. from WooGene B&G Co., Ltd..	16/20/16	CI
WooGene B&G Co., Ltd. announced that it has received KRW 3 billion in funding	15/20/15	CI
WooGene B&G Co., Ltd. announced that it expects to receive KRW 3 billion in funding	10/20/10	CI
An unknown buyer agreed to acquire 23.2% stake in WooGene Bio Co., Ltd. from WooGene B&G Co., Ltd. for KRW 2.9 billion.	16/19/16	CI
WooGene B&G Co., Ltd. announced that it expects to receive KRW 7.526523 billion in funding from Green Cross Veterinary Products Co., Ltd.	16/19/16	CI
WooGene B&G Co., Ltd. announced that it has received KRW 10 billion in funding from Hana Ventures, Aju Investment Co. Ltd., Mirae Asset Daewoo Co., Ltd. and other investor	14/19/14	CI
WooGene B&G Co., Ltd. agreed to acquire OSP Co., Ltd. from Taejun Kim, Hyewon Kim and Jiwon Kim for KRW 22.5 billion.	14/19/14	CI
WooGene B&G Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Hana Ventures, Aju Investment Co. Ltd., Mirae Asset Daewoo Co., Ltd.and another investor	01/19/01	CI
WooGene B&G Co., Ltd. announced that it has received KRW 5 billion in funding	03/19/03	CI
WooGene B&G Co., Ltd. announced that it expects to receive KRW 5 billion in funding	30/19/30	CI
WooGene B&G Co., Ltd. announced that it has received KRW 13 billion in funding from Hyundai Asset Management Co., Ltd.	20/16/20	CI
WooGene B&G Co., Ltd. announced that it expects to receive KRW 11 billion in funding from Hyundai Asset Management Co., Ltd. and other investors.	16/16/16	CI
WooGene B&G Co., Ltd.’s Equity Buyback announced on October 10, 2008 has expired.	02/14/02	CI
WooGene B&G Co., Ltd. Extends Equity Buyback till May 2, 2014	30/13/30	CI

WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Companyâs products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
WOOGENE B&G CO., LTD	-5.06%	2.44Cr
ZOETIS INC.	-13.20%	7.82TCr
ELANCO ANIMAL HEALTH INCORPORATED	+21.54%	894.96Cr
BLUESTAR ADISSEO COMPANY	+22.25%	361.7Cr
VIRBAC	-4.59%	309.02Cr
VIMIAN GROUP AB	+14.02%	168.29Cr
VETOQUINOL SA	-0.39%	129.92Cr
JINYU BIO-TECHNOLOGY CO., LTD.	-28.97%	117.84Cr
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-31.03%	115.19Cr
WUHAN KEQIAN BIOLOGY CO.,LTD	-21.79%	102.14Cr